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Abstract
Objective—Many African infants fail to receive their diagnostic HIV molecular test results and 
subsequently, antiretroviral therapy (ART). To determine whether a point-of-care molecular HIV 
test increases ART access for hospitalized Malawian infants, we simulated a point-of-care test 
using rapid HIV RNA polymerase chain reaction (Rapid PCR) and compared patient outcomes to 
an optimized standard care that included assessment with the World Health Organization (WHO) 
clinical algorithm for HIV infection plus a DNA PCR with a turnaround time of several weeks 
(standard care).
Design—Randomized controlled trial.
Methods—Hospitalized HIV-exposed Malawian infants <12 months old were randomized into 
Rapid PCR or standard care. Rapid PCR infants obtained molecular test results within 48 hours to 
facilitate immediate ART, similar to a point-of-care test. Standard care infants meeting clinical 
criteria were also offered inpatient ART. The primary outcome was appropriate in-hospital ART 
for DNA or RNA PCR-confirmed HIV-infected infants.
Results—300 infants were enrolled. A greater proportion of HIV-infected infants receiving 
Rapid PCR, versus standard care, started inpatient ART (72.3% vs 47.8%, p=0.016). Among 
molecular test-negative infants, 26.9% receiving standard care unnecessarily initiated inpatient 
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ART, versus 0.0% receiving Rapid PCR (p<0.001). Rapid PCR modestly reduced the median days 
to ART (3.0 vs 6.5, p=0.001) but did not influence outpatient follow-up for HIV-infected infants 
(78.1% vs 82.4%, P = 0.418).
Conclusions—Rapid PCR, versus an optimized standard care, increased the proportion of 
hospitalized HIV-infected infants initiating ART and reduced ART exposure in molecular test-
negative infants, without meaningfully impacting time to ART initiation or follow-up rates.
Keywords
point-of-care; early infant diagnosis of HIV; presumptive diagnosis; Africa; DNA PCR
Introduction
New pediatric HIV infection rates in Africa, home to >90% of the world’s 3.4 million HIV-
infected children, are slowing.1 Nevertheless, substantial challenges remain. African mother-
to-child HIV transmission rate targets are <5%, but most countries are not meeting this 
goal.2 Early antiretroviral therapy (ART) for HIV-infected infants reduces mortality,3–5 yet 
<25% of eligible African children receive ART.6 Low ART coverage is largely due to 
delayed diagnosis of infants,4 who require molecular diagnostic HIV testing with either HIV 
DNA polymerase chain reaction (PCR) or HIV RNA PCR. Both tests have limited 
availability and slow result turnaround time throughout Africa.7,8 These missed diagnostic 
opportunities contribute to high mortality rates for HIV-infected African infants.4
In Malawi, a southern African country with an 11% adult HIV prevalence,1 improving infant 
HIV care will require both community and facility-based strategies.9 Given the high HIV 
prevalence and advanced immunosuppression commonly present in hospitalized Malawian 
children,10,11 hospitals are key HIV care entry points. Routine in-hospital HIV testing, for 
example, can identify younger HIV-infected children and increase their access to ART.12,13 
But the approach has not fulfilled its potential, as many infants miss their DNA PCR results 
after testing and result disclosure delays.
One solution to existing DNA PCR system gaps would be a point-of-care infant HIV test 
that is simple, rapidly processed, and does not require a laboratory.7 Such a point-of-care 
test could eliminate many of the DNA PCR system barriers, so practitioners could 
expediently determine an infant’s HIV status and start ART before hospital discharge. The 
World Health Organization (WHO) clinical algorithm for identifying symptomatic HIV-
infected infants could meet these needs. However, it has not been widely implemented due 
to performance concerns,5,14–17 and its key clinical endpoints including ART initiation have 
not been rigorously studied. While preliminary studies with recently-developed molecular 
point-of-care infant HIV tests suggest that their sensitivity and specificity profiles will 
outperform the WHO algorithm,7 at this time the clinical implications of a point-of-care 
infant HIV test have not been thoroughly investigated.
Therefore, we conducted a randomized controlled trial to compare patient outcomes between 
an optimized standard care, defined as a pediatrician evaluation using the WHO algorithm in 
addition to an HIV DNA PCR test with results turnaround times of several weeks, versus a 
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rapid HIV RNA PCR test with a 48-hour turn-around time (Rapid PCR), which allows 
patients to receive definitive test results before hospital discharge. Consequently, this Rapid 
PCR test serves as a surrogate point-of-care infant molecular test, since it permits the 
clinician to use a definitive HIV status to determine hospital ART eligibility, similar to a 
true point-of-care test. We hypothesized that Rapid PCR would initiate a greater proportion 
of HIV-infected infants on ART during hospitalization and expose fewer molecular test-
negative infants to ART, compared to an optimized standard care.
Methods
Study Setting, Enrollment, and Definitions
This study occurred between February and November 2011 at Kamuzu Central Hospital 
(KCH) in Lilongwe, Malawi. KCH admits >13,000 children annually.10 Mother-infant pairs 
were offered routine HIV antibody testing in the pediatric wards,10 and were invited for 
enrollment if the infant was HIV-exposed and <12 months old. Study staff obtained written 
informed consent from caregivers. At enrollment, patients were randomized by computer-
generated permutation to either optimized standard care (WHO clinical algorithm evaluation 
plus DNA PCR) or Rapid PCR (on-site RNA PCR, with results returned within 48 hours, 
instead of standard care using the WHO clinical algorithm plus DNA PCR). We chose a 
randomized controlled study design after carefully considering multiple factors including 
what we believed to be the best methodological approach for answering our primary 
research question along with practical issues including overall feasibility, cost, and ethical 
considerations. The study pediatrician and caregivers were not blinded. All infants had a 
physical examination and chest radiograph interpreted by the study pediatrician. Clinical- 
and laboratory-confirmed diagnoses and treatments were according to Malawi and WHO 
guidelines or consensus recommendations.18–20 Patients were excluded if they were 
previously documented as HIV-uninfected or HIV-infected, or if they were HIV-exposed 
but unlikely to be HIV-infected because their mother was adherent to ART for >1 year. The 
latter group was excluded because ethical review determined that both the risk and costs of 
empiric ART initiation outweighed its potential benefits in this cadre of likely HIV-
uninfected children.
An infant could meet the definition of HIV exposure and be eligible for enrollment in two 
ways. First, HIV exposure included children, irrespective of breastfeeding status, never 
previously tested for HIV and born to an HIV-infected mother. Second, a child was also 
HIV-exposed if HIV DNA PCR negative or with an undetectable quantity of HIV virus on 
RNA PCR (<400 copies/ml) and breastfeeding from an HIV-infected mother <6 weeks after 
the date of either test. This HIV exposure definition did not rely upon HIV antibody 
positivity since both severely ill HIV-infected children and acutely HIV-infected children 
could be HIV antibody-negative. We defined HIV infection as infants with a positive HIV 
DNA PCR (standard care) or >10,000 copies/ml of HIV virus on RNA PCR (Rapid PCR). 
HIV molecular test-negative infants were participants that had either a negative HIV DNA 
PCR (standard care) or undetectable quantity of HIV virus on RNA PCR (<400 copies/ml 
[Rapid PCR]) irrespective of ongoing breastfeeding status. See Supplemental Digital 
Content 1, for additional definitions.
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Blood for HIV antibodies (Alere, Trinity Biotech) and either dried blood spot HIV DNA 
PCR (Amplicor HIV-1 DNA Test, version 1.5® [Roche Molecular Systems, Inc.]) or RNA 
PCR (Amplicor HIV-1 Monitor, version 1.5® [Roche Molecular Systems, Inc.]) were drawn 
from standard care and Rapid PCR patients, respectively, based upon randomization results. 
DNA PCR tests were routinely processed at the government KCH laboratory while RNA 
PCR tests were processed as prescribed by the manufacturer using manual extraction and 
PCR set-up (see manufacturer package insert for procedure details) at the University of 
North Carolina Project laboratory at KCH. A complete blood count with differential, malaria 
blood smear, blood culture, and a CD4 cell count percentage were collected on all infants 
and analyzed at the study laboratory.
Each child received a tuberculin skin test, which was assessed 48–72 hours after placement. 
Children at high risk for tuberculosis (see Supplemental Digital Content 1) had an induced 
sputum and gastric aspirate microscopy, evaluated by fluorescent microscopy, and culture 
using MGIT liquid media (Becton, Dickinson and Company) or Lowenstein-Jensen solid 
agar (Remel). Among children meeting WHO-defined pneumonia criteria or the 
Pneumocystis jirovecii pneumonia case definition (see Supplemental Digital Content 1), 
sputum was analyzed by immunofluorescence for P.jirovecii (Biorad). Sputum specimen 
quality was not evaluated, because no pediatric standards existed at the time of the study.21
WHO Algorithm Evaluation and ART Eligibility
Standard care infants were evaluated per the WHO algorithm (see Supplemental Digital 
Content 2). WHO algorithm-positive infants were HIV antibody-positive and had >2 
conditions (severe sepsis, severe or very severe pneumonia, or oral thrush). Alternatively, 
infants not meeting criteria of >2 conditions could still be WHO algorithm-positive if found 
with one AIDS-specific condition (P.jirovecii pneumonia, esophageal candidiasis, 
treatment-unresponsive severe malnutrition, extra-pulmonary tuberculosis, Kaposi sarcoma, 
cerebral toxoplasmosis, or cryptococcal meningitis). We classified HIV-exposed infants that 
tested HIV antibody-negative as ineligible for evaluation by the WHO algorithm, per their 
antibody-negative status.
If an infant was WHO algorithm-positive, caregivers were counseled that their infant was 
likely HIV-infected and would benefit from ART (stavudine, lamivudine, and nevirapine). 
The risks and benefits of commencing ART in a WHO algorithm-positive child were 
discussed with caregivers. Caregivers of Rapid PCR-positive infants were similarly 
counseled regarding ART.
Follow-up
Study staff followed infants, irrespective of HIV status, for at least one month after hospital 
discharge or ART initiation in a hospital-based study clinic to ensure receipt of molecular 
test results, re-review ART eligibility, and assess for adverse outcomes. ART was continued 
in WHO algorithm-positive infants taking ART subsequently found to be DNA PCR-
positive during follow-up. ART was stopped in DNA PCR-negative infants previously 
started on ART due to their in-hospital WHO algorithm-positive status. Caregivers of WHO 
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algorithm-negative infants testing DNA PCR-positive were re-counseled regarding HIV 
infection and ART. Immune reconstitution inflammatory syndrome (IRIS) was defined as 
infants with a new illness after ART and clinical signs as previously defined.22 HIV-infected 
and molecular test-negative infants still breastfeeding were transferred to a government HIV 
clinic once stable with a confirmed HIV status.
Ethical Approval
The Malawi National Health Science Research Committee, UNC-Chapel Hill School of 
Medicine and Baylor College of Medicine Institutional Review Boards approved this study. 
This trial was registered at ClinicalTrials.gov NCT01388452.
Statistical Analysis
Data were tested for normality using Q-Q plots and Shapiro-Wilk tests. Normally-
distributed data were described with mean and standard deviation, and were compared using 
a student’s t test. Non-parametric data were described with median and interquartile range, 
and were compared using the Mann-Whitney U test. Proportions were compared using 
Pearson’s chi-square or Fisher’s exact test; when a covariate had three or more categories, a 
global chi-square test was performed, and when significant, post-hoc individual pair-wise 
testing was performed, with alpha adjusted according to Bonferroni’s correction. All 
statistical analyses were performed using IBM SPSS Statistics version 20 (IBM Corporation, 
Armonk, NY).
Results
In all, 300 infants were randomized (150 per group [Figure 1]). Enrollment characteristics of 
both groups were similar (Table 1). The median age of all 300 subjects was 4.6 months, and 
153 (51%) were female. Although nearly 2/3 of mother-infant pairs, regardless of 
randomization, reported receipt of HIV prevention services, just 76 (25.3%) were receiving 
HIV care. We found that 234 (78.0%) subjects tested HIV antibody-positive with a normal 
mean CD4% (31.9%). The cohort’s overall HIV prevalence was 31.0% (either DNA PCR-
positive [standard care] or >10,000 copies/ml on RNA PCR [Rapid PCR]), with no 
prevalence difference between groups. The median age of the 66 infants who tested HIV 
antibody negative was 8.5 months (IQR 6.9–10.7); 50 (75.8%) of these infants were 
breastfeeding and six (9.1%) were HIV molecular test-positive. The majority of all patients 
reported cough (67.3%), difficulty breathing (51.7%), and fever (65.7%) at presentation, and 
52.6% had a WHO-defined abnormal chest radiograph.23
There were also no differences between the groups regarding hospital diagnoses or inpatient 
disposition (Table 2). Forty-four percent of the 119 HIV antibody-positive patients in the 
standard care group were WHO algorithm-positive and thus inpatient ART-eligible. The 
WHO algorithm achieved a sensitivity of 53.5%, specificity of 60.5%, and positive and 
negative predictive values of 43.4% and 69.7% for the 119 HIV antibody-positive standard 
care infants eligible for WHO algorithm evaluation. More than 60% of all infants met WHO 
pneumonia criteria. Sepsis was also common (44.7% standard care; 42.0% Rapid PCR), and 
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P. jirovecii pneumonia, malaria, and gastroenteritis were each found in one in four children. 
In all, 9.3% of patients died while hospitalized.
Rapid RNA PCR results were returned a mean of 30 days earlier than DNA PCR results 
(Table 3, p<0.001). In addition, a greater proportion of HIV-infected infants in the Rapid 
PCR group initiated ART in the hospital compared to standard care (34/47 [72.3%] vs 22/46 
[47.8%], p=0.016). Because of early deaths shortly after enrollment, not all HIV-infected 
infants in the Rapid PCR group received ART. No molecular test-negative infants 
randomized to Rapid PCR were incorrectly initiated on ART while hospitalized, compared 
to 28/104 (26.9%) receiving standard care (p<0.001). Of the 24 standard care DNA PCR-
positive infants who did not receive in-hospital ART, one (4.2%) WHO algorithm-positive 
infant died in the hospital before ART could be initiated, three (12.5%) were ineligible for 
inpatient ART due to a negative HIV antibody test, and twenty (83.3%) were ART-ineligible 
per negative inpatient algorithm status. Fourteen of the 20 (70.0%) antibody or algorithm-
negative PCR-positive infants who survived to hospital discharge also returned for follow-
up, all of whom initiated outpatient ART. The median time between molecular HIV testing 
and ART was reduced by 3.5 days for HIV-infected infants in the Rapid PCR group versus 
the standard care group (p=0.001), reflecting the fact that HIV-infected standard care infants 
received ART in a bimodal fashion (e.g., hospital-initiated if WHO algorithm-positive or 
outpatient-initiated if algorithm-negative but DNA PCR-positive).
In a subgroup analysis of WHO algorithm-positive and Rapid PCR-positive infants (data not 
shown), we found no difference between the groups in the average time from testing to in-
hospital ART (3.8 days, algorithm-positive vs 3.9 days, Rapid PCR-positive, p=0.884). Nor 
were any differences found in outpatient follow-up rates, including WHO algorithm and 
Rapid PCR-positive infants who were initiated on ART while hospitalized [37/43 (86.0%) 
vs 28/34 (82.4%), P = 0.631].
Lastly, of all 41 HIV-infected infants (DNA PCR-positive or >10,000 copies/ml on RNA 
PCR) started on inpatient ART and in care, three developed IRIS and one had a mild 
nevirapine rash at follow-up (data not shown). ART was continued in these patients. 
Furthermore, no differences in outpatient mortality or default rates were found among all 
HIV-infected infants stratified by inpatient ART (p=0.785, Table 4), suggesting that factors 
unassociated with ART may have influenced these unfavorable outcomes. We also 
examined the implications of ART in DNA PCR-negative infants. Of the 22 WHO 
algorithm-positive children on ART who were PCR-negative, 1 died shortly after ART 
initiation because of primary illness, 2 defaulted, and 1 developed a nevirapine-associated 
rash. These default and death rates were no different from ART naïve molecular test-
negative infants (Table 4).
Discussion
The widespread availability of a point-of-care molecular HIV test will revolutionize the care 
of African infants. However, this hope is largely inferred from studies showing the 
limitations of current care, rather than direct evaluation of key clinical endpoints of a point-
of-care test.4 Although several promising molecular point-of-care tests are in development, 
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none are yet approved for routine use.7 In this study, we accelerated the PCR reporting time 
from more than one month to just 48 hours, enabling us to simulate, and thus evaluate, a 
rapid molecular HIV test and its clinical implications for hospitalized infants. The Rapid 
PCR test we used here successfully achieved the same clinical endpoints that would be 
targeted by a point-of-care test performed in the hospital, including that all Rapid PCR 
subjects received their results and were offered ART if HIV-infected before discharge. Our 
data demonstrates that a rapid PCR test in hospitalized African infants, compared to an 
idealized standard care, greatly increases ART access but only modestly reduces the time 
between HIV testing and ART initiation for infants found to be HIV-infected. Rapid 
molecular testing also more effectively utilizes resources by eliminating unnecessary ART 
exposure for patients with a negative molecular HIV test.
Point-of-care serologic HIV tests have been in use for >10 years and offer a glimpse of what 
could be achieved with widespread implementation of an infant point-of-care molecular HIV 
test. Point-of-care serologic testing has been a key driver in the dramatic increase in HIV 
testing access for African adults in areas with limited laboratory support,24 and have ensured 
that almost every HIV-infected adult receives their test results, and hence a definitive HIV 
diagnosis, so that they can consider ART immediately.25–27 In our study, clinical staff 
consistently expressed an increased motivation to test Malawian infants for HIV since a 
rapid molecular test was available. This observation is supported by the unexpectedly short 
enrollment time-frame and suggests that a scale-up of point-of-care molecular testing should 
further increase infant access to HIV diagnostics. Our results also demonstrate for the first 
time that a high proportion of HIV-infected infants with positive rapid molecular tests 
received their results and commenced ART expediently.
Our data show that a Rapid PCR test, compared to optimized standard care, will enable 
clinicians to more proficiently prescribe ART to hospitalized HIV-infected infants. 
However, it was not yet known whether commencing ART during hospitalization is either a 
judicious use of resources, given historical 31.7%-32.7% initial attrition rates after discharge 
in ART-naïve patients,10,13 or safe, considering the likelihood of IRIS when starting ART in 
an acutely ill infant.28 Our results suggest that ART initiation should not be deferred until 
outpatient follow-up solely on the basis of initial default rates, as 82.4% of HIV-infected 
infants in the Rapid PCR group on ART returned for outpatient care. These initial follow-up 
rates are higher than previously reported,10,13 and could reflect greater caregiver motivation 
to follow-up after definitive infant diagnosis and prescription for ART. Recent evidence 
shows that hospital-identified HIV-infected children, once established in outpatient care, 
have one-year attrition rates no different than their community-identified counterparts.12 On 
the other hand, our high follow-up rates may partly reflect the controlled, more rigorous 
conditions of our study design and might not be replicable in a routine programmatic setting. 
We also found little reason to defer in-hospital ART initiation on the basis of a high 
incidence of IRIS or acute ART toxicities. These findings contrast with current clinical 
practice in Africa, by which providers delay ART initiation until outpatient care, largely on 
these concerns. Although we acknowledge that our follow-up duration was short, evidence 
suggests the majority of IRIS cases usually occur soon after ART initiation and within this 
study’s follow-up time-frame.28 Given that the hospital will be an important ART access 
point for African infants for the foreseeable future, our results warrant additional study of 
McCollum et al. Page 7






















longer-term care retention for HIV-affected infants first identified in the hospital, and of 
rates and severity of IRIS in HIV-infected hospitalized infants initiated on ART while 
recovering from an acute illness.
Our study applied the WHO clinical algorithm to all hospitalized HIV antibody-positive 
standard care subjects and offered ART if they were algorithm-positive. Standard program 
conditions throughout most African hospitals do not typically include routine use of the 
WHO clinical algorithm as implemented during this study. Instead, real-world standard care 
consists of infants waiting weeks for their DNA PCR results, with the majority defaulting 
before receiving their results and entering care.4 These data demonstrate that despite its 
shortcomings compared to Rapid PCR, routine use of the WHO algorithm can serve as a 
useful bridge between the currently-used DNA PCR testing system and the next-generation 
point-of-care molecular tests under development. Three aspects of our data support this 
position. First, nearly 50% of HIV-infected infants were initiated on ART in the standard 
care group before hospital discharge. Current evidence suggests that most of these infants 
may otherwise not have gained access to these life-saving medicines, especially if they were 
forced to wait at least one month for their DNA PCR results.4,13 Second, our data implies 
that starting ART on acutely ill HIV-infected infants may be safe, and that temporarily 
initiating ART on molecular test-negative infants could be equally benign. However, given 
our relatively small sample size, additional confirmatory research is needed to determine the 
true rates of IRIS and ART toxicities. Lastly, we found that the timeliness of ART initiation 
in WHO algorithm-positive infants (3.8 days) compared favorably with Rapid PCR-positive 
patients (3.9 days), thus allowing ART initiation prior to hospital discharge. Taken together, 
these data indicate that without a point-of-care molecular test, the WHO algorithm is still a 
useful tool that can help alleviate some of the inherent drawbacks of current infant HIV 
DNA PCR testing systems.
Our study has several weaknesses. We likely underestimated the prevalence of ART toxicity 
since we relied upon clinical screening for side-effects followed by laboratory confirmation 
on suspected cases only. With this approach, we found no cases of nevirapine-associated 
hepatotoxicity, for example, although subclinical cases could have been missed. However, 
the effect of any subclinical toxicity was likely minimal, since outcomes were no different 
when we controlled for ART exposure. This study is also limited by our unblinded study 
design, which increases the likelihood of observer and participant bias. However, a blinded 
design would be unethical, given that it would be inappropriate to counsel algorithm-
positive and -negative patients identically to Rapid PCR patients in regard to HIV status. 
Lastly, our hospital-based results may not reflect outpatient performance of either a point-of-
care molecular diagnostic or the WHO algorithm, for two reasons. First, our 48-hour Rapid 
PCR test, if used in outpatient clinics, would require two separate visits (one for blood 
collection and another to deliver results), whereas only one visit is needed for a true point-
of-care test. Second, outpatient HIV prevalence is lower and patients are generally less ill 
than in the hospital, such that fewer HIV-infected infants meet WHO clinical criteria in a 
clinic setting. Thus, the generalizability of our results to the outpatient setting would require 
further study.
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In summary, we simulated a point-of-care molecular HIV test in a hospital setting, and 
found that Rapid PCR, compared to an optimized standard care predicated on routine use of 
the WHO clinical algorithm, greatly improves ART access for HIV-infected infants, while 
minimizing unnecessary ART exposure for infants with negative molecular HIV test results. 
The WHO algorithm compared favorably to Rapid PCR from the perspective of ART timing 
and initial outpatient follow-up for Rapid PCR and WHO algorithm-positive infants. 
Therefore, until a point-of-care molecular HIV test is widely available, we recommend the 
routine use of the WHO clinical algorithm for hospitalized African infants in resource-
constrained settings.
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reaction.
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Demographic Age in months, median (IQR) 5.1 (2.3 – 8.7) 4.2 (1.7 – 8.0) 0.299
Females, n (%) 74 (49.3) 79 (52.7) 0.564
Breastfeeding, n (%) 123 (82.0) 124 (82.7) 0.880
Vaccinations up-to-date, n (%) 85/149 (57.0) 79/147 (53.7) 0.567
Infant enrolled in HIV care, n (%) 38 (25.3) 38 (25.3) 1.000
PMTCT received by mother, n (%) 96/148 (64.9) 93/148 (62.8) 0.717
PMTCT received by infant, n (%) 96 (64.0) 91 (60.7) 0.551
Presenting clinical signs Temperature in °C, mean (SD) 37.0 (0.8) 37.0 (0.8) 0.787
Heart rate (beats per minute), mean (SD) 149 (23) 149 (20) 0.898
Respiratory rate (breaths per minute), mean (SD) 55 (19) 55 (16) 0.726
Oxygen saturation, median (IQR) 97 (94 – 100) 98 (95 – 100) 0.452
Weight for height z score, mean (SD) −1.05 (2.04) −0.98 (1.81) 0.781
Laboratories HIV antibody test positive, n (%) 119 (79.3) 115 (76.7) 0.577
HIV molecular test positive, n (%)1 46 (30.7) 47 (31.3) 0.901
CD4%, mean (SD) 30.4 (14.1) 33.4 (14.3) 0.072
Hemoglobin (g/dL), mean (SD) 9.7 (2.4) 10.2 (2.8) 0.086
Malaria blood film positive, n (%) 5/148 (3.4) 6/150 (4.0) 1.000
Blood culture positive, n (%) 9/149 (6.0) 7/150 (4.7) 0.598
Radiography, n (%) Abnormal chest radiograph 81/146 (55.5) 71/143 (49.7) 0.321
PCR indicates polymerase chain reaction; IQR, interquartile range; HIV, human immunodeficiency virus; PMTCT, prevention of mother-to-child 
transmission; SD, standard deviation.
1
46 standard care patients were DNA PCR-positive and 47 Rapid PCR patients had >10,000 viral copies/ml on RNA PCR






























Final Diagnoses, n (%) WHO clinical algorithm-positive1 53/119 (44.5) NA
Rapid PCR-positive NA 47 (31.3) -
Severe Pneumonia 63 (42.0) 61 (40.7) 0.815
Very severe pneumonia 29 (19.3) 31 (20.7) 0.773
Pneumocystis jirovecii pneumonia2 40 (26.7) 37 (24.7) 0.692
Pulmonary Tuberculosis3 19 (12.7) 14 (9.3) 0.356
Severe Acute Malnutrition 32 (21.3) 29 (19.3) 0.667
Sepsis4 67 (44.7) 63 (42.0) 0.641
Malaria5 35 (23.3) 38 (25.3) 0.686
Meningitis6 5 (3.3) 5 (3.3) 1.000
Gastroenteritis 38 (25.3) 38 (25.3) 1.000
Esophageal candida 8 (5.3) 5 (3.3) 0.572
Length of hospitalization in days, median (IQR) 4 (4 – 7) 5 (4 – 6) 0.133
Hospital Outcome, n (%) 0.492
Discharged 137 (91.3) 131 (87.3)
Died 11 (7.3) 17 (11.3)
Absconded 2 (1.3) 2 (1.3)
PCR indicates polymerase chain reaction; WHO, World Health Organization; NA, not applicable; HIV, human immunodeficiency virus; IQR, 
interquartile range; ART, antiretroviral therapy.
1
31 standard care infants tested HIV antibody-negative and were not eligible to be evaluated by the WHO algorithm.
2
3 and 37 standard care patients were confirmed and probable Pneumocystis jirovecii cases compared to 6 and 31 Rapid PCR patients, respectively.
3
1 and 18 standard care patients were confirmed and probable pulmonary tuberculosis cases compared to 1 and 13 Rapid PCR patients, 
respectively.
4
7 and 60 standard care patients were confirmed and probable sepsis cases compared to 9 and 54 Rapid PCR patients, respectively.
5
6 and 29 standard care patients were confirmed and probable malaria cases compared to 5 and 33 Rapid PCR patients, respectively.
6
1 and 4 standard care patients were confirmed and probable bacterial meningitis cases compared to 0 and 5 Rapid PCR patients, respectively.






























HIV molecular test status 0.901
Positive1 46 (30.7) 47 (31.3)
Negative2 104 (69.3) 103 (68.7)
Days to molecular test results, mean (SD) All 32.5 (9.2) 2.5 (0.9) <0.001
Hospital ART initiation, n (%) HIV molecular test positive1,3 22/46 (47.8) 34/47 (72.3) 0.016
HIV molecular test negative2,4 28/104 (26.9) 0/103 (0.0) <0.001
Days to ART, median (IQR) HIV molecular test positive1,5 6.5 (3 – 28) 3.0 (3 – 4) 0.001
Outpatient follow-up, n (%) All 113/137 (82.5) 108/131 (82.4) 0.993
HIV indicates human immunodeficiency virus; PCR, polymerase chain reaction; SD, standard deviation; ART, antiretroviral therapy.
1
Patients were either DNA PCR-positive (standard care) or had >10,000 viral copies/ml on RNA PCR (Rapid PCR).
2
Patients were either DNA PCR-negative (standard care) or had <400 viral copies/ml on RNA PCR (Rapid PCR).
3
1 and 2 HIV-infected infants in the standard care group that met the WHO clinical algorithm criteria either died or absconded before inpatient 
ART initiation, respectively. 13 and 0 HIV-infected infants in the Rapid PCR group either died or absconded before inpatient ART initiation, 
respectively.
4
Zero DNA PCR-negative infants in the standard care group that did not meet WHO clinical algorithm criteria died before hospital discharge. 4 
and 2 infants with <400 viral copies/ml on RNA PCR in the Rapid PCR group either died or absconded before hospital discharge, respectively.
5
HIV-infected standard care infants were started on ART either in the hospital if WHO algorithm-positive or as an outpatient if algorithm-negative 
but DNA PCR-positive. Rapid PCR infants were started on ART in the hospital only.
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Table 4
Influence of ART on short-term patient outcomes.










Outpatient follow-up, n (%) 0.785 0.194
Yes 41 (74.5) 13 (65.0) 21 (95.5) 116 (79.5)
No, default 9 (16.4) 5 (25.0) 1 (4.5) 27 (18.5)
No, death 5 (9.1) 2 (10.0) 0 (0.0) 3 (2.1)
ART indicates antiretroviral therapy; HIV, human immunodeficiency virus; PCR, polymerase chain reaction.
1
Patients were either DNA PCR-positive (standard care) or had >10,000 viral copies/ml on RNA PCR (Rapid PCR).
2
Patients were either DNA PCR-negative (standard care) or had <400 viral copies/ml on RNA PCR (Rapid PCR).
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